Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2012-01-09 | Xenon Pharmaceuticals (USA) Genentech, a member of the Roche Group (USA - Switzerland) | compounds and companion diagnostics for the potential treatment of pain | pain | CNS diseases | ||
2012-01-09 | Leo Pharma (Denmark) Virobay (USA) | undisclosed compound | psoriasis | development licensing |
Autoimmune diseases - Dermatological diseases | |
2012-01-06 | AnaptysBio (USA) Novartis (Switzerland) | therapeutic antibodies to multiple oncology-related therapeutic targets. | cancer | R&D | Cancer Oncology | |
2012-01-05 | Octoplus (The Netherlands) undisclosed top-5 pharmaceutical company | controlled release formulation that combines the client\'s optimized product candidate with Octoplus\'s proprietary drug delivery technology PolyActive | undisclosed | R&D | ||
2012-01-05 | Boehringer Ingelheim (Germany) FORMA Therapeutics (USA) | small molecule drugs against oncology-relevant protein-protein interactions | cancer | R&D | Cancer Oncology | |
2012-01-05 | Midatech (UK) MonoSol Rx (USA) | diabetes | joint-venture |
Metabolic diseases | Joint-venture agreement | |
2012-01-05 | GSK (UK) ChemoCentryx (USA - CA) | CCX354 | rheumatoid arthritis | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Exercise of an option agreement | |
2012-01-04 | AM-Pharma (The Netherlands) | nomination |
Inflammatory diseases | Nomination | ||
2011-12-22 | Vivalis (France) undisclosed animal health company | EB66® cell line for the production of several animal health vaccine | licensing | Veterinary medicine | ||
2011-12-21 | Arecor (UK) Eli Lilly (USA) | stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly | R&D | |||
2011-12-20 | Genmab (Denmark) - undisclosed pharma company | DuoBody™ Platform | solid tumors |
R&D | Cancer Oncology | |
2011-12-20 | Affibody (Sweden) Nuclisome (Sweden) | new cancer therapeutics | cancer | R&D | Cancer Oncology | |
2011-12-19 | Summit (UK) Muscular Dystrophy Association (USA) Parent Project Muscular Dystrophy (USA) Charley’s Fund (USA) Cure Duchenne (USA) Foundation to Eradicate Duchenne (USA) Nash Avery Foundation (USA) | SMT C1100 | Duchenne muscular dystrophy | Genetic diseases - Neuromuscular diseases - Rare diseases | Establishment of a new subsidiary in the EU | |
2011-12-19 | Amgen (USA - CA) Watson Pharmaceuticals (USA - NJ), now Actavis (Ireland), now Allergan (Ireland) | oncology biosimilar products | development commercialisation |
Cancer - Oncology | Development agreement | |
2011-12-16 | Pharming (The Netherlands) Renova Life (USA) | development and supply of founder transgenic rabbits | hemophilia A | services |
Hematological diseases - Genetic diseases - Rare diseases | Services contract |
2011-12-16 | Transgene (France) French League against Cancer (France) | new anticancer biotherapies | cancer | R&D |
Cancer - Oncology | R&D agreement |
2011-12-16 | GSK (UK) GAVI Alliance | pneumococcal vaccine, Synflorix® | pneumococcal disease | supply |
Infectious diseases | Collaboration agreement |
2011-12-15 | Morphosys (Germany) Novozymes (Denmark) | Slonomics technology | licensing |
Licensing agreement | ||
2011-12-15 | GSK (UK) The University of Dundee (UK) | Huntington’s disease | R&D |
Rare diseases - Genetic diseases - Neurodegenerative diseases | R&D agreement | |
2011-12-15 | Shire (UK-USA) Atlas Venture (USA) | collaboration |
Rare diseases | Collaboration agreement |